Clinical Trial Update: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating the safety and efficacy of FURESTEM-AD Inj. in patients with moderately subacute and chronic atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• FURESTEM-AD Inj.

Snippet

Sponsor: Kang Stem Biotech Co., Ltd. | Conditions: Atopic Dermatitis | Phase 1, Phase 2 | Status: COMPLETED